<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font6" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font7" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font8" size="8" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font9" size="7" family="GillSans" color="#000000"/>
	<fontspec id="font10" size="5" family="GillSans" color="#000000"/>
	<fontspec id="font11" size="7" family="Symbol" color="#000000"/>
	<fontspec id="font12" size="7" family="GillSans,Italic" color="#000000"/>
<text top="41" left="55" width="162" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Genetic Vaccines and Therapy 2007, 5 :5<i>Genetic Vaccines and Therapy</i></text>
<text top="41" left="394" width="160" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.gvt-journal.com/content/5/1/5</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="142" segment_no="9" tag_type="text">Page 5 of 9<b>5</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="143" segment_no="10" tag_type="text">(page number not for citation purposes)</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="99" segment_no="5" tag_type="text">HIV-positive patients [40]. Two children were enrolled in</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="100" segment_no="5" tag_type="text">this study, a nine-year-old and an eight-year-old who were</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="101" segment_no="5" tag_type="text">both on HAART. CD34 + bone marrow cells from the par-<i>(page number not for citation purposes)</i></text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="102" segment_no="5" tag_type="text">ticipants were transduced with two retroviral vectors, one<a href="">[40]</a>. Two children were enrolled in</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="103" segment_no="5" tag_type="text">encoding a "humanized" dominant negative REV protein</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="104" segment_no="5" tag_type="text">(huM10) and one encoding an internal control for gene</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="105" segment_no="5" tag_type="text">marking (FX) that is not translated. A humanized protein</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="106" segment_no="5" tag_type="text">is one in which the codon usage has been optimized for</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="107" segment_no="5" tag_type="text">mammalian expression. Following infusion of the modi-</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="108" segment_no="5" tag_type="text">fied cells, huM10 and FX could be detected in peripheral</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="109" segment_no="5" tag_type="text">blood mononuclear cells (PBMC) for 1–3 months. Dur-</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="110" segment_no="5" tag_type="text">ing a two-year follow-up period, levels of huM10 and FX</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="111" segment_no="5" tag_type="text">expression dropped to at or below the limit of detection.</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="112" segment_no="5" tag_type="text">In one patient, during a period of non-compliance to</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="113" segment_no="5" tag_type="text">HAART regimen, PBMCs containing huM10 reappeared</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="114" segment_no="5" tag_type="text">suggesting a selective increase in survival for PBMCs con-</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="115" segment_no="5" tag_type="text">taining huM10 during periods of high viral loads [40].</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="116" segment_no="7" tag_type="text">Using a chimeric receptor approach, Walker et al . (2000)</text>
<text top="684" left="55" width="241" height="13" font="font4" id="p1_t23" reading_order_no="117" segment_no="7" tag_type="text">investigated the effect of CD4 ζ -modified syngeneic T-cells</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="118" segment_no="7" tag_type="text">in HIV-positive patients [41]. The study was conducted</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="119" segment_no="7" tag_type="text">using sets of twins, one of whom was HIV-positive and the</text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="120" segment_no="7" tag_type="text">other HIV-negative. The HIV-negative twin acted as the<a href="">ads [40].</a></text>
<text top="462" left="313" width="241" height="10" font="font4" id="p1_t27" reading_order_no="121" segment_no="4" tag_type="text">donor for syngeneic T-cells (either CD8 + or CD4 + ), while</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t28" reading_order_no="122" segment_no="4" tag_type="text">the HIV-positive twin was the recipient. T cells from the<i>et al</i></text>
<text top="484" left="313" width="241" height="13" font="font4" id="p1_t29" reading_order_no="123" segment_no="4" tag_type="text">donor were genetically modified ex vivo to express CD4 ζ</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t30" reading_order_no="124" segment_no="4" tag_type="text">and then transfused into the recipient twin. The study was</text>
<text top="510" left="313" width="107" height="9" font="font4" id="p1_t31" reading_order_no="125" segment_no="4" tag_type="text">performed in two phases.</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t32" reading_order_no="126" segment_no="6" tag_type="text">In the first phase, 27 patients were enrolled and received</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t33" reading_order_no="127" segment_no="6" tag_type="text">one to six cell infusions every eight weeks. Three patients<a href="">[41</a>]. The study was conducted</text>
<text top="556" left="313" width="241" height="10" font="font4" id="p1_t34" reading_order_no="128" segment_no="6" tag_type="text">received 10 7 modified cells, while the remaining 24</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t35" reading_order_no="129" segment_no="6" tag_type="text">patients were randomly assigned to four groups, receiving</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t36" reading_order_no="130" segment_no="6" tag_type="text">either 10 8 , 10 9 , or 10 10 modified cells or 10 10 unmodified</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t37" reading_order_no="131" segment_no="6" tag_type="text">cells. The researchers observed that one of three subjects</text>
<text top="603" left="313" width="241" height="10" font="font4" id="p1_t38" reading_order_no="132" segment_no="6" tag_type="text">receiving 10 7 cells and four of six subjects receiving 10 8</text>
<text top="613" left="313" width="241" height="13" font="font4" id="p1_t39" reading_order_no="133" segment_no="6" tag_type="text">cells showed low levels of CD4 ζ expression. In three of</text>
<text top="625" left="313" width="242" height="13" font="font4" id="p1_t40" reading_order_no="134" segment_no="6" tag_type="text">these five CD4 ζ -positive patients, CD4 ζ was no longer</text>
<text top="637" left="313" width="241" height="13" font="font4" id="p1_t41" reading_order_no="135" segment_no="6" tag_type="text">detected after one to three days, but in two of them, CD4 ζ</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t42" reading_order_no="136" segment_no="6" tag_type="text">could be detected for up to 2 and 24 weeks, respectively.</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t43" reading_order_no="137" segment_no="6" tag_type="text">In 11 of 12 patients receiving higher doses and multiple<i>ex vivo </i></text>
<text top="672" left="313" width="241" height="13" font="font4" id="p1_t44" reading_order_no="138" segment_no="6" tag_type="text">infusions of modified CD8 + cells, CD4 ζ could be detected</text>
<text top="686" left="313" width="184" height="9" font="font4" id="p1_t45" reading_order_no="139" segment_no="6" tag_type="text">for up to 15 to 40 weeks post-infusion [41].</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t46" reading_order_no="140" segment_no="8" tag_type="text">In the second phase of the Walker et al . trial, 33 patients</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t47" reading_order_no="141" segment_no="8" tag_type="text">were enrolled, 25 from the previous phase and 8 new par-</text>
<text top="87" left="55" width="164" height="7" font="font8" id="p1_t48" reading_order_no="2" segment_no="2" tag_type="title">Table 1: Summary of results of clinical trials</text>
<text top="105" left="66" width="33" height="6" font="font9" id="p1_t49" reading_order_no="3" segment_no="3" tag_type="table">Target cells</text>
<text top="105" left="137" width="20" height="6" font="font9" id="p1_t50" reading_order_no="4" segment_no="3" tag_type="table">Vector</text>
<text top="105" left="216" width="29" height="6" font="font9" id="p1_t51" reading_order_no="5" segment_no="3" tag_type="table">Transgene</text>
<text top="105" left="304" width="49" height="6" font="font9" id="p1_t52" reading_order_no="6" segment_no="3" tag_type="table">Anti-HIV method</text>
<text top="105" left="457" width="20" height="6" font="font9" id="p1_t53" reading_order_no="7" segment_no="3" tag_type="table">Results</text>
<text top="126" left="74" width="17" height="6" font="font9" id="p1_t54" reading_order_no="8" segment_no="3" tag_type="table">CD8 +</text>
<text top="126" left="114" width="30" height="6" font="font9" id="p1_t55" reading_order_no="9" segment_no="3" tag_type="table">Retrovirus</text>
<text top="126" left="188" width="16" height="6" font="font9" id="p1_t56" reading_order_no="10" segment_no="3" tag_type="table">HyTk</text>
<text top="126" left="281" width="79" height="6" font="font9" id="p1_t57" reading_order_no="11" segment_no="3" tag_type="table">Introduction of suicide gene</text>
<text top="126" left="384" width="118" height="6" font="font9" id="p1_t58" reading_order_no="12" segment_no="3" tag_type="table">CTL response cleared modified cells [16].</text>
<text top="135" left="74" width="17" height="6" font="font9" id="p1_t59" reading_order_no="13" segment_no="3" tag_type="table">CD4 +</text>
<text top="135" left="114" width="66" height="6" font="font9" id="p1_t60" reading_order_no="14" segment_no="3" tag_type="table">Gold-particle-mediated</text>
<text top="135" left="188" width="25" height="6" font="font9" id="p1_t61" reading_order_no="15" segment_no="3" tag_type="table">Rev M10</text>
<text top="135" left="281" width="91" height="6" font="font9" id="p1_t62" reading_order_no="16" segment_no="3" tag_type="table">Transdominant negative protein</text>
<text top="135" left="384" width="138" height="6" font="font9" id="p1_t63" reading_order_no="17" segment_no="3" tag_type="table">Detected Rev M10 until 2 months post infusion,</text>
<text top="142" left="384" width="71" height="6" font="font9" id="p1_t64" reading_order_no="18" segment_no="3" tag_type="table">preferential survival [36].</text>
<text top="151" left="74" width="17" height="6" font="font9" id="p1_t65" reading_order_no="19" segment_no="3" tag_type="table">CD4 +</text>
<text top="151" left="114" width="30" height="6" font="font9" id="p1_t66" reading_order_no="20" segment_no="3" tag_type="table">Retrovirus</text>
<text top="151" left="188" width="25" height="6" font="font9" id="p1_t67" reading_order_no="21" segment_no="3" tag_type="table">Rev M10</text>
<text top="151" left="281" width="91" height="6" font="font9" id="p1_t68" reading_order_no="22" segment_no="3" tag_type="table">Transdominant negative protein</text>
<text top="151" left="384" width="138" height="6" font="font9" id="p1_t69" reading_order_no="23" segment_no="3" tag_type="table">Detected Rev M10 until 6 months post infusion,</text>
<text top="158" left="384" width="71" height="6" font="font9" id="p1_t70" reading_order_no="24" segment_no="3" tag_type="table">preferential survival [37].</text>
<text top="167" left="74" width="17" height="6" font="font9" id="p1_t71" reading_order_no="25" segment_no="3" tag_type="table">CD4 +</text>
<text top="167" left="114" width="30" height="6" font="font9" id="p1_t72" reading_order_no="26" segment_no="3" tag_type="table">Retrovirus</text>
<text top="167" left="188" width="84" height="6" font="font9" id="p1_t73" reading_order_no="27" segment_no="3" tag_type="table">TdRev and/or anti-sense TAR</text>
<text top="167" left="281" width="95" height="6" font="font9" id="p1_t74" reading_order_no="28" segment_no="3" tag_type="table">Transdominant negative proteins</text>
<text top="174" left="281" width="56" height="6" font="font9" id="p1_t75" reading_order_no="29" segment_no="3" tag_type="table">and anti-sense RNA</text>
<text top="167" left="384" width="161" height="6" font="font9" id="p1_t76" reading_order_no="30" segment_no="3" tag_type="table">Anti-HIV genes consistently detected for &gt;100 weeks in</text>
<text top="174" left="384" width="165" height="6" font="font9" id="p1_t77" reading_order_no="31" segment_no="3" tag_type="table">six of six patients. Preferential survival of transduced cells</text>
<text top="181" left="384" width="148" height="6" font="font9" id="p1_t78" reading_order_no="32" segment_no="3" tag_type="table">during a period of high viral load in one patient [47].</text>
<text top="190" left="73" width="20" height="6" font="font9" id="p1_t79" reading_order_no="33" segment_no="3" tag_type="table">CD34 +</text>
<text top="190" left="114" width="30" height="6" font="font9" id="p1_t80" reading_order_no="34" segment_no="3" tag_type="table">Retrovirus</text>
<text top="190" left="188" width="18" height="6" font="font9" id="p1_t81" reading_order_no="35" segment_no="3" tag_type="table">TdRev</text>
<text top="190" left="281" width="91" height="6" font="font9" id="p1_t82" reading_order_no="36" segment_no="3" tag_type="table">Transdominant negative protein</text>
<text top="190" left="384" width="161" height="6" font="font9" id="p1_t83" reading_order_no="37" segment_no="3" tag_type="table">One patient died due to relapse to Hodgkin's disease. In</text>
<text top="197" left="384" width="155" height="6" font="font9" id="p1_t84" reading_order_no="38" segment_no="3" tag_type="table">second patient, detected vector in the progeny for &gt;3</text>
<text top="204" left="384" width="161" height="6" font="font9" id="p1_t85" reading_order_no="39" segment_no="3" tag_type="table">years, remission of leukemia and good viral load control<a href="">usion [41].</a></text>
<text top="211" left="384" width="142" height="6" font="font9" id="p1_t86" reading_order_no="40" segment_no="3" tag_type="table">achieved by administering HAART that cannot be</text>
<text top="218" left="384" width="98" height="6" font="font9" id="p1_t87" reading_order_no="41" segment_no="3" tag_type="table">attributed to gene therapy [38,39].<i>et al</i></text>
<text top="227" left="73" width="20" height="6" font="font9" id="p1_t88" reading_order_no="42" segment_no="3" tag_type="table">CD34 +</text>
<text top="227" left="114" width="30" height="6" font="font9" id="p1_t89" reading_order_no="43" segment_no="3" tag_type="table">Retrovirus</text>
<text top="227" left="188" width="19" height="6" font="font9" id="p1_t90" reading_order_no="44" segment_no="3" tag_type="table">huM10<b>Table 1: Summary of results of clinical trials</b></text>
<text top="227" left="281" width="91" height="6" font="font9" id="p1_t91" reading_order_no="45" segment_no="3" tag_type="table">Transdominant negative protein</text>
<text top="227" left="384" width="130" height="6" font="font9" id="p1_t92" reading_order_no="46" segment_no="3" tag_type="table">huM10 could be detected in peripheral blood</text>
<text top="234" left="384" width="150" height="6" font="font9" id="p1_t93" reading_order_no="47" segment_no="3" tag_type="table">mononuclear cells (PBMC) for 1–3 months and then</text>
<text top="241" left="384" width="164" height="6" font="font9" id="p1_t94" reading_order_no="48" segment_no="3" tag_type="table">dropped to at or below the limit of detection over a two</text>
<text top="248" left="384" width="163" height="6" font="font9" id="p1_t95" reading_order_no="49" segment_no="3" tag_type="table">year follow-up period. Preferential survival of transduced</text>
<text top="255" left="384" width="162" height="6" font="font9" id="p1_t96" reading_order_no="50" segment_no="3" tag_type="table">cells during a period of high viral load in one patient [40].</text>
<text top="264" left="74" width="17" height="6" font="font9" id="p1_t97" reading_order_no="51" segment_no="3" tag_type="table">CD4 +</text>
<text top="264" left="114" width="30" height="6" font="font9" id="p1_t98" reading_order_no="52" segment_no="3" tag_type="table">Retrovirus</text>
<text top="262" left="188" width="17" height="9" font="font9" id="p1_t99" reading_order_no="53" segment_no="3" tag_type="table">CD4 ζ</text>
<text top="264" left="281" width="53" height="6" font="font9" id="p1_t100" reading_order_no="54" segment_no="3" tag_type="table">Chimeric receptor</text>
<text top="264" left="384" width="154" height="6" font="font9" id="p1_t101" reading_order_no="55" segment_no="3" tag_type="table">Decrease of greater than 0.5 log mean in rectal tissue-</text>
<text top="269" left="384" width="161" height="9" font="font9" id="p1_t102" reading_order_no="56" segment_no="3" tag_type="table">associated HIV RNA for at least 14 days, detected CD4 ζ</text>
<text top="278" left="384" width="98" height="6" font="font9" id="p1_t103" reading_order_no="57" segment_no="3" tag_type="table">in 1–3% of PBMCs at 8 weeks [42]</text>
<text top="287" left="74" width="17" height="6" font="font9" id="p1_t104" reading_order_no="58" segment_no="3" tag_type="table">CD4 +</text>
<text top="287" left="114" width="30" height="6" font="font9" id="p1_t105" reading_order_no="59" segment_no="3" tag_type="table">Retrovirus</text>
<text top="285" left="188" width="17" height="9" font="font9" id="p1_t106" reading_order_no="60" segment_no="3" tag_type="table">CD4 ζ</text>
<text top="287" left="281" width="53" height="6" font="font9" id="p1_t107" reading_order_no="61" segment_no="3" tag_type="table">Chimeric receptor</text>
<text top="285" left="384" width="154" height="9" font="font9" id="p1_t108" reading_order_no="62" segment_no="3" tag_type="table">Good expression of CD4 ζ for at least 24 weeks in all</text>
<text top="294" left="384" width="162" height="6" font="font9" id="p1_t109" reading_order_no="63" segment_no="3" tag_type="table">patients; no difference between control and study group</text>
<text top="301" left="384" width="13" height="6" font="font9" id="p1_t110" reading_order_no="64" segment_no="3" tag_type="table">[43].</text>
<text top="310" left="59" width="47" height="6" font="font9" id="p1_t111" reading_order_no="65" segment_no="3" tag_type="table">CD4 + and CD8 +</text>
<text top="310" left="114" width="30" height="6" font="font9" id="p1_t112" reading_order_no="66" segment_no="3" tag_type="table">Retrovirus</text>
<text top="308" left="188" width="17" height="9" font="font9" id="p1_t113" reading_order_no="67" segment_no="3" tag_type="table">CD4 ζ</text>
<text top="310" left="281" width="53" height="6" font="font9" id="p1_t114" reading_order_no="68" segment_no="3" tag_type="table">Chimeric receptor</text>
<text top="310" left="384" width="166" height="6" font="font9" id="p1_t115" reading_order_no="69" segment_no="3" tag_type="table">In 11 of 12 patients who received higher doses of modified</text>
<text top="315" left="384" width="159" height="9" font="font9" id="p1_t116" reading_order_no="70" segment_no="3" tag_type="table">ζ CD8 + cells (10 9 or 10 10 ), CD4 could be detected post-</text>
<text top="324" left="384" width="153" height="6" font="font9" id="p1_t117" reading_order_no="71" segment_no="3" tag_type="table">infusion for at least 15–40 weeks when they received</text>
<text top="331" left="384" width="164" height="6" font="font9" id="p1_t118" reading_order_no="72" segment_no="3" tag_type="table">additional infusions of modified cells. The group receiving</text>
<text top="338" left="384" width="151" height="6" font="font9" id="p1_t119" reading_order_no="73" segment_no="3" tag_type="table">IL-2 along with modified CD8 + cells showed a higher</text>
<text top="343" left="384" width="164" height="9" font="font9" id="p1_t120" reading_order_no="74" segment_no="3" tag_type="table">ζ persistence of CD4 as compared to the group receiving</text>
<text top="352" left="384" width="152" height="6" font="font9" id="p1_t121" reading_order_no="75" segment_no="3" tag_type="table">no IL-2. In patients who received modified CD8 + and</text>
<text top="359" left="384" width="166" height="6" font="font9" id="p1_t122" reading_order_no="76" segment_no="3" tag_type="table">CD4 + cells, the cells were detected in the peripheral blood</text>
<text top="366" left="384" width="103" height="6" font="font9" id="p1_t123" reading_order_no="77" segment_no="3" tag_type="table">for at least 1 year post-infusion [41].</text>
<text top="375" left="73" width="20" height="6" font="font9" id="p1_t124" reading_order_no="78" segment_no="3" tag_type="table">CD34 +</text>
<text top="375" left="114" width="30" height="6" font="font9" id="p1_t125" reading_order_no="79" segment_no="3" tag_type="table">Retrovirus</text>
<text top="375" left="188" width="35" height="6" font="font9" id="p1_t126" reading_order_no="80" segment_no="3" tag_type="table">(RRE) decoy</text>
<text top="375" left="281" width="33" height="6" font="font9" id="p1_t127" reading_order_no="81" segment_no="3" tag_type="table">RNA decoy</text>
<text top="375" left="384" width="162" height="6" font="font9" id="p1_t128" reading_order_no="82" segment_no="3" tag_type="table">RRE-decoy-containing leukocytes could be isolated from</text>
<text top="382" left="384" width="144" height="6" font="font9" id="p1_t129" reading_order_no="83" segment_no="3" tag_type="table">peripheral blood even 1 year post-infusion but the</text>
<text top="389" left="384" width="99" height="6" font="font9" id="p1_t130" reading_order_no="84" segment_no="3" tag_type="table">numbers were extremely low [44].</text>
<text top="398" left="74" width="17" height="6" font="font9" id="p1_t131" reading_order_no="85" segment_no="3" tag_type="table">CD4 +</text>
<text top="398" left="114" width="30" height="6" font="font9" id="p1_t132" reading_order_no="86" segment_no="3" tag_type="table">Retrovirus</text>
<text top="398" left="188" width="15" height="6" font="font9" id="p1_t133" reading_order_no="87" segment_no="3" tag_type="table">RRz2</text>
<text top="398" left="281" width="28" height="6" font="font9" id="p1_t134" reading_order_no="88" segment_no="3" tag_type="table">Ribozyme</text>
<text top="398" left="384" width="160" height="6" font="font9" id="p1_t135" reading_order_no="89" segment_no="3" tag_type="table">Over a 4 year period, PBMCs containing both RRz2 and</text>
<text top="405" left="384" width="109" height="6" font="font9" id="p1_t136" reading_order_no="90" segment_no="3" tag_type="table">LNL6 were consistently detected [46].</text>
<text top="414" left="73" width="20" height="6" font="font9" id="p1_t137" reading_order_no="91" segment_no="3" tag_type="table">CD34 +</text>
<text top="414" left="114" width="30" height="6" font="font9" id="p1_t138" reading_order_no="92" segment_no="3" tag_type="table">Retrovirus</text>
<text top="414" left="188" width="45" height="6" font="font12" id="p1_t139" reading_order_no="93" segment_no="3" tag_type="table">tat / vpr ribozyme</text>
<text top="414" left="281" width="28" height="6" font="font9" id="p1_t140" reading_order_no="94" segment_no="3" tag_type="table">Ribozyme</text>
<text top="414" left="384" width="152" height="6" font="font9" id="p1_t141" reading_order_no="95" segment_no="3" tag_type="table">Vector was detected in naïve T cells for &gt;3 years; no</text>
<text top="421" left="384" width="159" height="6" font="font9" id="p1_t142" reading_order_no="96" segment_no="3" tag_type="table">correlation between changes in viremia or CD4+ T cell</text>
<text top="428" left="384" width="164" height="6" font="font9" id="p1_t143" reading_order_no="97" segment_no="3" tag_type="table">counts with vector expression or its detection in any cell</text>
<text top="435" left="384" width="27" height="6" font="font9" id="p1_t144" reading_order_no="98" segment_no="3" tag_type="table">type [45].</text>
</page>
</pdf2xml>
